Biomimetic nerve guidance conduit containing engineered exosomes of adipose-derived stem cells promotes peripheral nerve regeneration.
Exosomes
Nerve guidance conduit
Neurotrophin-3
Peripheral nerve
Regeneration
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
06 08 2021
06 08 2021
Historique:
received:
21
04
2021
accepted:
18
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Efficient and stable delivery of neurotrophic factors (NTFs) is crucial to provide suitable microenvironment for peripheral nerve regeneration. Neurotrophin-3 (NT-3) is an important NTF during peripheral nerve regeneration which is scarce in the first few weeks of nerve defect. Exosomes are nanovesicles and have been served as promising candidate for biocarrier. In this work, NT-3 mRNA was encapsulated in adipose-derived stem cell (ADSC)-derived exosomes (Exo NT-3 mRNA was encapsulated in exosomes by forcedly expression of NT-3 mRNA in the donor ADSCs. Exo The engineered exosomes could deliver NT-3 mRNA to the recipient cells efficiently and translated into functional protein. The constructed NGC could realize stable release of exosomes at least for 2 weeks. After NGC implantation in vivo, Exo In this work, NGC was constructed to allow exosome-mediated NT-3 mRNA delivery. After Exo
Sections du résumé
BACKGROUND
Efficient and stable delivery of neurotrophic factors (NTFs) is crucial to provide suitable microenvironment for peripheral nerve regeneration. Neurotrophin-3 (NT-3) is an important NTF during peripheral nerve regeneration which is scarce in the first few weeks of nerve defect. Exosomes are nanovesicles and have been served as promising candidate for biocarrier. In this work, NT-3 mRNA was encapsulated in adipose-derived stem cell (ADSC)-derived exosomes (Exo
METHOD
NT-3 mRNA was encapsulated in exosomes by forcedly expression of NT-3 mRNA in the donor ADSCs. Exo
RESULTS
The engineered exosomes could deliver NT-3 mRNA to the recipient cells efficiently and translated into functional protein. The constructed NGC could realize stable release of exosomes at least for 2 weeks. After NGC implantation in vivo, Exo
CONCLUSION
In this work, NGC was constructed to allow exosome-mediated NT-3 mRNA delivery. After Exo
Identifiants
pubmed: 34362437
doi: 10.1186/s13287-021-02528-x
pii: 10.1186/s13287-021-02528-x
pmc: PMC8343914
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
442Informations de copyright
© 2021. The Author(s).
Références
Ann Neurol. 2014 Feb;75(2):255-65
pubmed: 24339129
Ann Clin Lab Sci. 2016 Dec;46(6):578-585
pubmed: 27993869
Nature. 1994 Jan 13;367(6459):170-3
pubmed: 8114912
J Gene Med. 2011 Nov;13(11):591-601
pubmed: 21954128
Microsurgery. 1989;10(3):226-35
pubmed: 2796719
Adv Healthc Mater. 2020 Jul;9(13):e2000268
pubmed: 32431051
ACS Appl Mater Interfaces. 2018 Dec 19;10(50):43327-43342
pubmed: 30460837
Adv Healthc Mater. 2020 Jun;9(11):e1901570
pubmed: 32338461
Mol Ther. 2019 Apr 10;27(4):710-728
pubmed: 30846391
Biomaterials. 2011 Jul;32(20):4506-16
pubmed: 21397324
Cell Biochem Biophys. 2014 Apr;68(3):449-54
pubmed: 24037713
Int Rev Neurobiol. 2009;87:127-39
pubmed: 19682636
J Comp Neurol. 1998 Jan 5;390(1):102-11
pubmed: 9456179
Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
Adv Drug Deliv Rev. 2016 Jan 15;96:54-76
pubmed: 25962984
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):E1707-E1716
pubmed: 28137843
Biomaterials. 2009 Aug;30(22):3711-22
pubmed: 19375792
Neurosurg Clin N Am. 1991 Jan;2(1):43-56
pubmed: 1668265
ACS Biomater Sci Eng. 2020 Mar 9;6(3):1590-1602
pubmed: 33455380
Biomaterials. 2015 May;49:77-89
pubmed: 25725557
J Physiol. 1991 Apr;435:41-63
pubmed: 1770443
J Appl Physiol (1985). 2014 Dec 1;117(11):1215-30
pubmed: 25277737
J Neurosci Res. 1999 Apr 1;56(1):1-7
pubmed: 10213469
Stem Cell Res Ther. 2017 Aug 14;8(1):189
pubmed: 28807034
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Biomaterials. 1997 Apr;18(8):583-90
pubmed: 9134157
Methods. 2008 Jun;45(2):115-20
pubmed: 18593609
Nat Biomed Eng. 2020 Jan;4(1):69-83
pubmed: 31844155
Biofabrication. 2019 Sep 10;11(4):042001
pubmed: 31315105
J Biomed Mater Res A. 2005 Nov 1;75(2):374-86
pubmed: 16088902
J Biomed Mater Res A. 2020 Mar;108(3):545-556
pubmed: 31702867
Theranostics. 2018 Jan 1;8(1):237-255
pubmed: 29290805
Science. 2014 Oct 31;346(6209):626-9
pubmed: 25359972
J Cell Biol. 1993 Oct;123(2):455-65
pubmed: 8408225
Biotechnol Bioeng. 2009 Dec 15;104(6):1207-14
pubmed: 19603426
J Control Release. 2016 Oct 28;240:227-234
pubmed: 26718856
J Cell Biol. 1992 Oct;119(1):45-54
pubmed: 1527172
Biotechnol Adv. 2018 Jan - Feb;36(1):328-334
pubmed: 29248680
Med Devices (Auckl). 2014 Dec 01;7:405-24
pubmed: 25489251
Glia. 2013 Nov;61(11):1795-806
pubmed: 24038411
J Control Release. 2020 Jan 10;317:78-95
pubmed: 31756394
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
Exp Neurol. 2010 May;223(1):77-85
pubmed: 19348799
Biomaterials. 2007 Dec;28(36):5526-35
pubmed: 17884161
Biotechnol Appl Biochem. 2013 Nov-Dec;60(6):547-56
pubmed: 23909973
Theranostics. 2019 Oct 11;9(24):7403-7416
pubmed: 31695776
Neurosurg Focus. 2004 May 15;16(5):E1
pubmed: 15174821
J Surg Res. 2020 Mar;247:128-135
pubmed: 31776022
Inflamm Res. 2009 Jan;58(1):1-8
pubmed: 19132498
J Am Coll Cardiol. 2018 Jan 16;71(2):193-200
pubmed: 29325643
Neurol Res. 2004 Mar;26(2):186-94
pubmed: 15072638